Grade Group 1前列腺癌表现出肿瘤定义性雄激素受体驱动程序
研究刻画低级别Grade Group 1(GG1)前列腺癌的雄激素受体(AR)染色质结合图谱,发现GG1肿瘤缺乏独特的AR cistrome,AR优先结合肿瘤定义性顺式调控元件,其增强子活性及靶基因表达与高级别癌无显著差异,表观遗传学上支持将其视为癌症并与良性组织区分。
要点
- GG1前列腺癌与高级别癌类似,AR优先结合肿瘤定义性顺式调控元件。
- GG1肿瘤缺乏独特的AR cistrome,增强子活性及靶基因表达与高级别癌无显著差异。
- 表观遗传学证据支持GG1为真性癌症,与良性前列腺组织明确区分。
核心结论
- GG1肿瘤缺乏独特AR cistrome,AR优先结合肿瘤定义性顺式调控元件,表观遗传学支持其为癌症并与良性组织区分。
研究设计与样本
- 研究刻画低级别GG1前列腺癌的AR染色质结合图谱,并与高级别癌及正常前列腺上皮比较。
主要发现
- GG1肿瘤缺乏独特AR cistrome,AR优先结合肿瘤定义性顺式调控元件。
- GG1肿瘤中这些区域增强子活性及对应靶基因表达与高级别癌无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Grade group 1 (GG1) primary prostate cancers with a pathologic Gleason score of 6 are considered indolent and generally not associated with fatal outcomes, so treatment is not indicated for most cases. These low-grade cancers have an overall negligible risk of locoregional progression and metastasis to distant organs, which is why there is an ongoing debate about whether these lesions should be reclassified as "noncancerous". However, the underlying molecular activity of key disease drivers, such as the androgen receptor (AR), have thus far not been thoroughly characterized in low-grade tumors. Therefore, we set out to delineate the AR chromatin-binding landscape in low-grade GG1 prostate cancers to gain insights into whether these AR-driven programs are actually tumor-specific or are normal prostate epithelium-like. These analyses showed that GG1 tumors do not harbor a distinct AR cistrome and, similar to higher-grade cancers, AR preferentially binds to tumor-defining cis-regulatory elements. Furthermore, the enhancer activity of these regions and the expression of their respective target genes were not significantly different in GG1 tumors. From an epigenetic perspective, this finding supports the cancer designation currently given to these low-grade tumors and clearly distinguishes them from noncancerous benign tissue. PATIENT SUMMARY: We characterized the molecular activity of the androgen receptor protein, which drives prostate cancer disease, in low-grade tumors. Our results show that these tumors are true cancers and are clearly separate from benign prostate tissue despite their low clinical aggressiveness.
引用
- Linder S, Severson TM, van der Mijn KJC, et al. Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs. Eur Urol. 2023. PMID: 37271632. doi:10.1016/j.eururo.2023.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。